Meat processors hamper Zilmax study; Biofarma owners embark on stake sale;

@FiercePharma: Daiichi Sankyo sells off Ranbaxy's problems to Sun Pharma - FiercePharmaManufacturing. More | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read marketing story: Sanofi aims for outcomes with new Chief Patient Officer. Article | Follow @TracyStaton

@EricPFierce: Daniel Fabricant leaves FDA where he regulated dietary supplements, returning to its lobbying group NPA as CEO. News via NutraIngredients-USA | Follow @EricPFierce

@CarlyHFierce: Teva entreats SCOTUS to block Copaxone generics till patent case wraps. Story | Follow @CarlyHFierce

> Merck ($MRK) wants to test controversial Zilmax on 240,000 U.S. cattle to prove its safety, but meat processors won't take animals fed with the additive, leaving feedlot owners reluctant to participate. Report

> Owners of Turkish company Biofarma Pharmaceutical have hired Goldman Sachs to begin the process of selling a stake in the drugmaker. News

> The Affordable Care Act has triggered double-digit increases in demand for pharmaceuticals, new data suggests. More

> McKesson ($MCK) says shareholders in its takeover target Celesio can tender their shares for an additional two-week period. News

> Almost a third of patients never fill the prescriptions for medicines they're told to take, a Canadian study has found. Report (sub. req.)

Medical Device News

@FierceMedDev: JenaValve pockets another $10M as it vies with Medtronic, Edwards. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Merck KGaA signs on to sell Auxogyn's IVF test. Article | Follow @VarunSaxena2

@EmilyWFierce: Electrical epidural stimulation helped four paralyzed men regain use of their lower limbs. More | Follow @EmilyWFierce

@MichaelGFierce: ICYMI: The year in nanotech drug delivery. Report from FierceDrugDelivery | Follow @MichaelGFierce

> Daktari Diagnostics brings in $13M to fund its HIV test. News

> Deerfield unveils a $1.6B new fund as med tech VC lags. Story

> Sequent bags $20M to get its aneurysm tech on the U.S. market. More

Biotech News

@FierceBiotech: Lilly preps a PhIII study as breast cancer drug race heats up. Story | Follow @FierceBiotech

@JohnCFierce: Versant gambles $12M on Swiss PI3K/mTOR cancer drug upstart--Piqur in Basel. Article | Follow @JohnCFierce

@DamianFierce: Here's FierceBiotech's look at every drug developer IPO from the first quarter. Report | Follow @DamianFierce

@EmilyMFierce: Study: Fewer clinical trials, less animal research conducted on diseases of the poor. More from FierceBiotech Research | Follow @EmilyMFierce

> Deerfield eyeing new biotech investments after launching $1.6B fund. Story

> Alkermes hits PhIII goal line with 'blockbuster' long-acting schizophrenia drug. More

> TetraLogic bags lymphoma therapy in $13M buyout. Item

Biotech Research News

> Lilly, Pfizer partner with Lieber Institute on brain research. Item

> Daiichi Sankyo, UCSF strike deal to combat neurodegeneration. Story

> Vitamin B-3 could slow progression of muscle-wasting disorder. Article

> Caffeine-based compound targets tau deposits in Alzheimer's. More

> Study: Fewer clinical trials, less animal research conducted on diseases of the poor. News

> Breast cancer gene BRCA1 linked to brain development. Report

Pharma Manufacturing News

> Daiichi Sankyo sells off Ranbaxy's problems to Sun Pharma. Report

> UPM putting plant it bought from Pfizer to more use. News

> Lilly well-positioned with track-and-trace deadlines advancing. Article

> FDA is adding inspectors in China but for now it has only two. Story

> China's WuXi invests in edible anti-counterfeiting tech. More

> GSK logistics program improves on-time delivery to 90%. Item

And Finally... A new study suggests a link between the use of antidepressants during pregnancy and a higher risk of premature birth. Report (sub. req.)

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.